What is the recommended dose of Trelegy (fluticasone furoate, umeclidinium, and vilanterol) for Chronic Obstructive Pulmonary Disease (COPD)?

From the Guidelines

Trelegy Ellipta should be prescribed for COPD at a standard dose of one inhalation once daily, containing 100 mcg fluticasone furoate, 62.5 mcg umeclidinium, and 25 mcg vilanterol. This recommendation is based on the most recent and highest quality studies, which demonstrate the efficacy of this triple therapy approach in reducing exacerbations and improving lung function in patients with moderate to severe COPD 1. The medication should be taken at the same time each day for consistent results, with the inhaler held horizontally and the cover slid down until a click is heard.

Key points to consider when prescribing Trelegy Ellipta include:

• The importance of proper inhaler technique to ensure effective delivery of the medication
• The need for patients to rinse their mouth after use to prevent thrush
• The potential for increased risk of pneumonia and other adverse effects associated with inhaled corticosteroids
• The importance of regular monitoring and follow-up to assess the effectiveness of the medication and adjust the treatment plan as needed

It is also important to note that Trelegy Ellipta combines three medications: an inhaled corticosteroid (fluticasone) to reduce airway inflammation, a long-acting muscarinic antagonist (umeclidinium) to relax airway muscles, and a long-acting beta-agonist (vilanterol) to open airways. This triple therapy approach is particularly effective for patients with moderate to severe COPD who experience frequent exacerbations despite dual therapy 1. Patients should not stop taking the medication without consulting their healthcare provider, even if symptoms improve.

From the Research

Trelegy Dose for COPD

• The recommended dose of Trelegy Ellipta for the maintenance treatment of adults with moderate to severe chronic obstructive pulmonary disease (COPD) is one inhalation once daily 2.
• Trelegy Ellipta is a dry powder inhaler containing fluticasone furoate (inhaled corticosteroid [ICS]), vilanterol trifenatate (long-acting beta2 agonist [LABA]), and umeclidinium bromide (long-acting muscarinic antagonist [LAMA]) 2.
• The combination of fluticasone furoate, umeclidinium, and vilanterol has been shown to be effective in improving lung function, symptoms, and quality of life in patients with COPD 3, 4, 5, 6.
• The safety profile of Trelegy Ellipta has been evaluated in several studies, and it has been found to be generally well-tolerated, with a low incidence of adverse events such as cardiovascular effects and pneumonia 3, 5, 6.

Key Components and Their Effects

• Fluticasone furoate: an inhaled corticosteroid (ICS) that helps to reduce inflammation in the lungs 2.
• Umeclidinium bromide: a long-acting muscarinic antagonist (LAMA) that helps to relax the airway muscles and improve breathing 2.
• Vilanterol trifenatate: a long-acting beta2 agonist (LABA) that helps to relax the airway muscles and improve breathing 2.

Clinical Evidence

• Studies have shown that the combination of fluticasone furoate, umeclidinium, and vilanterol is effective in reducing the rate of moderate-severe exacerbations, improving trough FEV1, and improving quality of life in patients with COPD 3, 4, 5.
• The IMPACT study, a large trial comparing umeclidinium/fluticasone furoate/vilanterol with both fluticasone furoate/vilanterol and umeclidinium/vilanterol combinations, showed that triple therapy had a greater effect compared to dual therapies in reducing the rate of moderate-severe exacerbations, improving trough FEV1, and improving quality of life 5.